about
The evolving role of response-adapted PET imaging in Hodgkin lymphomaRisk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclinesAdvanced hodgkin lymphoma: a new era of therapy.Hodgkin disease-an ever-evolving therapy.Cardiovascular disease after cancer therapy.A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.The clinical performance evaluation of novel protein chips for eleven biomarkers detection and the diagnostic model studyReduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid.Clinical outcomes and prognostic factors of empirical antifungal therapy with itraconazole in the patients with hematological malignancies: a prospective multicenter observational study in Korea.Current status of prognostication in classical Hodgkin lymphoma.An update on emerging drugs for Hodgkin lymphoma.Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives.Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.Precision therapy for lymphoma--current state and future directions.Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials.Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma.Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass.Hodgkin lymphoma: highlights from the 2012 European School of Hematology International Conference.Blood biomarkers in adults with lymph node enlargement contribute to diagnostic significance of malignancy.High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors.Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
P2860
Q26750993-6DB922E2-C19B-4E97-A391-8C2B31768889Q33640172-80EA5334-57E1-4565-A664-9E281142169FQ34194160-D6A867FB-5B89-422B-8BFB-4BBF4F38C6E7Q34463426-C5CAAF5F-3944-47D6-BFC6-1FBF8597EB1BQ34604429-6F9A02F9-1BBF-47AA-BB62-45DFE057234FQ35925674-EF03734B-D654-4423-A444-6CEC1D3FA116Q36492734-09F662A6-8EA2-4439-874D-C431934D019CQ37235341-C45F5DFF-BD61-4A94-8B88-234FBB2B5C7FQ37418841-004AB871-8F02-40E9-9D04-9D1185AA626DQ38185063-BFCBD1EE-5031-4390-AC6E-C46D91784A56Q38205874-9F399E70-F27E-4CBA-B036-F74A7B8B9A14Q38205880-9F7A38FD-BF61-491B-B20A-014BA60F142AQ38205923-33E3FA85-086E-478A-B5BA-3EF720F371D0Q38241102-5D5701C8-8EBD-4B35-8C02-7214746BA7D3Q40040274-97857C7E-D577-47A8-A3C8-4898006A7F90Q41592435-7A9DBB02-8AE8-42F9-97A9-AF2132F7811AQ44611640-70404B99-1BF3-4095-B0BB-083F7F7EFC4DQ45825739-55C886DA-DDA0-44D2-B384-EF72B74F8788Q47164637-A72C3537-D009-4998-9E2A-04F9A07183AFQ49578208-BE0544F3-59CA-4C8A-82E9-43DB777B0756Q50600769-3195A59E-7814-4136-88FC-DEAD0C2CB64A
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
State of the art in the treatment of Hodgkin lymphoma.
@en
type
label
State of the art in the treatment of Hodgkin lymphoma.
@en
prefLabel
State of the art in the treatment of Hodgkin lymphoma.
@en
P2093
P2860
P1476
State of the art in the treatment of Hodgkin lymphoma.
@en
P2093
Andreas Engert
Dennis A Eichenauer
Peter Borchmann
P2860
P304
P356
10.1038/NRCLINONC.2012.91
P407
P577
2012-06-12T00:00:00Z